Yarrow Bioscience (YARW) EPS (Basic) Growth (1y) (2018 - 2026)
Powered by 
Analysis
Yarrow Bioscience (YARW) EPS (Basic) Growth (1y) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | -0.10% |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 284.05% |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | -130.68% |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | -15.94% |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -108.11% |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | -91.06% |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 39.99% |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 13.91% |
| 10 | Yarrow Bioscience | 25.25 Mn | 2.33 Mn | - | 47.92% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 47.92% |
| Mar 31, 2026 | 58.46% |
| Jun 30, 2025 | 39.06% |
| Mar 31, 2025 | -37.50% |
| Dec 31, 2024 | 53.14% |
| Sep 30, 2024 | 85.77% |
| Jun 30, 2024 | 92.81% |
| Mar 31, 2024 | 91.50% |
| Dec 31, 2023 | 80.70% |
| Sep 30, 2023 | -1,128.60% |
| Jun 30, 2023 | -1,999.64% |
| Mar 31, 2023 | -2,148.44% |
| Dec 31, 2022 | -1,288.58% |
| Sep 30, 2022 | 60.09% |
| Jun 30, 2022 | 62.25% |
| Mar 31, 2022 | 120.05% |
| Dec 31, 2021 | 68.56% |
| Sep 30, 2021 | -177.67% |
| Jun 30, 2021 | 67.91% |
| Mar 31, 2021 | 55.57% |